Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul-Aug;10(4):481-485.
doi: 10.4103/idoj.IDOJ_29_19.

Topical Ciclopirox Olamine 1%: Revisiting a Unique Antifungal

Sidharth Sonthalia  1 , Mahima Agrawal  2 , V N Sehgal  3
Affiliations

Topical Ciclopirox Olamine 1%: Revisiting a Unique Antifungal

Sidharth Sonthalia et al. Indian Dermatol Online J. 2019 Jul-Aug.

Abstract

The injudicious use of antifungals, indiscriminate use of corticosteroids for instant relief, persistence of predisposing factors like sweat retention and uncontrolled diabetes, and emerging resistance to antifungals across the globe have rendered the management of an erstwhile simple infection, the superficial cutaneous mycoses highly complicated and tricky. Ciclopirox is an old yet efficacious, versatile, and safe topical antifungal of the hydroxypyridone family. Despite its numerous beneficial properties over the majority of other topical antifungals, it remains underutilized.

Keywords: Candida; ciclopirox olamine; dermatophyte; mycoses; pityriasis versicolor; seborrheic dermatitis; tinea.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Markus A. Hydroxy-pyridones. Outstanding biological properties. In: Shuster S, editor. Hydroxy-Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis. Berlin: Springer-Verlag; 1999. pp. 1–10.
    1. Gupta AK. Ciclopirox: An overview. Int J Dermatol. 2001;40:305–10. - PubMed
    1. Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010;70:2133–52. - PubMed
    1. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol. 2003;149:296–305. - PubMed
    1. Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs. 1985;29:330–41. - PubMed